About US
Contact us
-
Takeda gets conditional EC approval for $62bn Shire acquisitionTakeda Pharmaceutical has received a conditional approval from the European Commission (EC) for the $62bn proposed acquisition of Irish biopharmaceutical company Shire. The EC clearance is conditiona2018/11/22
-
Sobi’s Gamifant obtains FDA approval to treat Primary HLHSobi and Novimmune have secured approval from the US Food and Drug Administration (FDA) for Gamifant (emapalumab-lzsg), the first and only treatment indicated for Primary Hemophagocytic Lymphohistiocy2018/11/22
-
Alvotech teams with Fuji Pharma for biosimilar portfolio in JapanIceland-based Alvotech has signed a deal for commercialisation of its biosimilar portfolio in Japan in an exclusive partnership agreement with Fuji Pharma. Under the partnership, Alvotech will develo2018/11/21
-
Merck and Palantir to form JV to advance cancer researchMerck has signed a non-binding term sheet to establish a joint venture (JV) with data analytics firm Palantir Technologies to support the advancement of cancer research. The JV will be known as Syntr2018/11/21
-
Pfizer, Merck KGaA's Bavencio flunks another trial, this time in ovarian cancerMark another tally for Pfizer and Merck KGaA’s Bavencio in the “loss” column. Monday, the drugmakersreportedthat their immuno-oncology drug had failed a phase 3 trial in previously treated ovarian ca2018/11/20
-
Eli Lilly weighs $200M-plus sale of declining China drug portfolio: reportThe news comes amid a long turnaround effort that’s just now starting to bear fruit. Lilly has launched 10 new drugs since 2014, not just in diabetes but also in high-growth markets such as cancer a2018/11/20
-
United Therapeutics reaches $1.2bn licensing deal with ArenaBiotechnology company United Therapeutics has signed a licensing deal worth up to $1.2bn with biopharmaceutical firm Arena Pharmaceuticals for a hypertension drug candidate, ralinepag. Ralinepag is A2018/11/19
-
M&As this week: Nestle Health, InvaGen, TakedaNestle Healthhas acquired a 19% stake in Aimmune Therapeutics for $98m. The companies have also extended a prior agreement for developing food allergy treatments by two years. The agreement allows Ai2018/11/19
-
FDA agrees to review Roche’s Tecentriq combination for breast cancerThe US Food and Drug Administration (FDA) has accorded priority review status to the supplemental biologics licence application (sBLA) of Roche’s Tecentriq (atezolizumab) as a combination therapy for2018/11/16
-
Pfizer loses Lyrica patent case in UK Supreme CourtThe UK Supreme Court has ruled against Pfizer in a long running legal case involving a second medical use patent for its Lyrica (pregabalin) drug. Lyrica was initially developed for the treatment of2018/11/16